Open AccessSerum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection
Author(s) -
Duygu Fazilet,
Tekin Koruk Suda,
Aksoy Nurten
Publication year - 2011
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20473
Subject(s) - arylesterase , paraoxonase , gastroenterology , medicine , pon1 , hepatitis b , hepatitis b virus , hepatitis , immunology , endocrinology , genotype , chemistry , virus , biochemistry , oxidative stress , gene
Abstract The aim of this study was to determine and evaluate the activity of paraoxonase and arylesterase enzymes in various clinical forms of hepatitis B infection and to investigate the correlation between these parameters and chronic disease course/fibrosis. Overall, 40 patients diagnosed as hepatitis B carriers (CIHBV), 40 chronic active hepatitis B (CAHBV) patients, and 40 healthy adults (control group) between 18 and 65 years of age were enrolled the study. Serum paraoxonase and arylesterase activities were measured spectrophotometrically. Their activities were significantly lower in patients with CAHBV compared with CIHBV patients or with control group patients ( P <0.001). There was a negative correlation between alanine aminotransferase levels and theactivity of paraoxonase and arylesterase ( r =−0.38, P =0.001 and r =−0.28, P =0.002, respectively). A statistically significant negative correlation was found between arylesterase activity in the sera of CAHBV patients and HBV DNA levels (ρ=−0.33, P =0.03). On the contrary, no correlation was found between paraoxonase levels and HBV DNA levels ( P >0.05). The histology activity index of CAHBV patients did not correlate with paraoxonase and arylesterase activities ( P >0.05). In light of these findings, it may be assumed that during the progression of an inactive hepatitis B carrier to being actively infected, reduced paraoxonase and arylesterase activities may be observed. J. Clin. Lab. Anal. 25:311–316, 2011. © 2011 Wiley‐Liss, Inc.